Guggenheim Capital LLC Bei Gene, Ltd. Transaction History

Guggenheim Capital LLC

$10.6 Billion
Q1 2025

A detailed history of Guggenheim Capital LLC transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Guggenheim Capital LLC holds 8,681 shares of BGNE stock, worth $1.97 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

8,681

Previous 4,569 90.0%

Holding current value

$1.97 Million

Previous $843,000 133.45%

% of portfolio

0.02%

Previous 0.01%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	BUY	$175.1 - $226.71 $720,011 - $932,231	4,112 Added 90.0%	8,681 $1.97 Million
Q4 2024 Feb 13, 2025	BUY	$174.72 - $246.04 $798,295 - $1.12 Million	4,569 New	4,569 $843,000
Q1 2022 May 16, 2022	SELL	$146.52 - $269.56 $113,846 - $209,448	-777 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$248.56 - $389.34 $1.62 Million - $2.53 Million	-6,499 Reduced 89.32%	777 $211,000
Q3 2021 Nov 15, 2021	SELL	$249.6 - $403.14 $331,219 - $534,966	-1,327 Reduced 15.42%	7,276 $2.64 Million
Q2 2021 Aug 13, 2021	BUY	$292.75 - $367.01 $198,191 - $248,465	677 Added 8.54%	8,603 $2.95 Million
Q1 2021 May 13, 2021	SELL	$260.64 - $382.12 $798,600 - $1.17 Million	-3,064 Reduced 27.88%	7,926 $2.76 Million
Q4 2020 Feb 16, 2021	BUY	$221.31 - $316.61 $975,534 - $1.4 Million	4,408 Added 66.97%	10,990 $2.84 Million
Q3 2020 Nov 13, 2020	SELL	$189.18 - $286.44 $1.87 Million - $2.82 Million	-9,862 Reduced 59.97%	6,582 $1.89 Million
Q2 2020 Aug 14, 2020	BUY	$123.9 - $195.41 $303,926 - $479,340	2,453 Added 17.53%	16,444 $3.1 Million
Q1 2020 Jun 02, 2020	SELL	$121.84 - $173.19 $357,600 - $508,312	-2,935 Reduced 17.34%	13,991 $1.72 Million
Q4 2019 Feb 14, 2020	BUY	$115.78 - $208.34 $1.96 Million - $3.53 Million	16,926 New	16,926 $2.81 Million
Q2 2018 Aug 14, 2018	SELL	$152.5 - $216.77 $851,407 - $1.21 Million	-5,583 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$97.41 - $177.22 $54,354 - $98,888	558 Added 11.1%	5,583 $938,000
Q4 2017 Feb 14, 2018	SELL	$79.6 - $114.73 $1.09 Million - $1.57 Million	-13,675 Reduced 73.13%	5,025 $491,000
Q3 2017 Nov 14, 2017	BUY	$66.19 - $103.46 $1.24 Million - $1.93 Million	18,700	18,700 $1.94 Million

Others Institutions Holding BGNE

# of Institutions

294

Shares Held

40.1M

Call Options Held

111K

Put Options Held

114K

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $23.5B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Guggenheim Capital LLC with notifications on news.

Account

Guggenheim Capital LLC Bei Gene, Ltd. Transaction History